Immunomodulatory activity of hyaluronidase is associated with metabolic adaptations during acute inflammation
- 70 Downloads
Objective and design
Investigate survival outcomes, and immunological and metabolomic effects of hyaluronidase (Hz) treatment during mouse models of acute inflammation and sepsis.
Survival of C57Bl/6 mice was monitored after lethal challenge with lipopolysaccharide (LPS) or cecal and ligation puncture (CLP)-induced sepsis and treated with Hz or saline. Mice were also challenged with LPS and treated with Hz for leukocyte counting, cytokine quantification and determination of metabolomic profiles in the peritoneal fluid.
Hz treatment improved survival outcomes after lethal challenge with LPS or CLP-induced sepsis. LPS challenge promoted acute neutrophil accumulation and production of interleukin-1β (IL-1β) and IL-6 in the peritoneum, whereas Hz treatment suppressed neutrophil infiltration and cytokine production. We further characterized the metabolomic alterations caused by LPS challenge, which predicted activity of metabolic pathways related to fatty acids and eicosanoids. Hz treatment had a profound effect over the metabolic response, reflected by reductions of the relative levels of fatty acids.
Collectively, these data demonstrate that Hz treatment is associated with metabolic reprogramming of pathways that sustain the inflammatory response.
KeywordsHyaluronidase Hyaluronic acid Sepsis Acute inflammation Metabolomics
This study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP grant #2009/07169-5, #2014/07125-6 and EMU #2015/00658-1 to LF; FAPESP scholarship #2007/04741-4 to CB); the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq grant #302514/2015-5); and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Brasil (CAPES)–Código de Financiamento 001 (process #1746212, #88882.317663/2019-01 and #88887.363659/2019-00 to LG; #150991/2011-8 to CB).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- 8.da Silva BC, Gelfuso GM, Pereira PAT, de Assis PA, Tefé-Silva C, Ramos SG, et al. Hyaluronidase-loaded PLGA Microparticles as a new strategy for the treatment of pulmonary fibrosis. Tissue Eng Part A. 2014;21:246–56.Google Scholar
- 11.Huang Z, Zhao C, Chen Y, Cowell JA, Wei G, Kultti A, et al. Recombinant human hyaluronidase PH20 does not stimulate an acute inflammatory response and inhibits lipopolysaccharide-induced neutrophil recruitment in the air pouch model of inflammation. J Immunol. 2014;192:5285–95.PubMedCrossRefPubMedCentralGoogle Scholar
- 14.Weis S, Carlos AR, Moita MR, Singh S, Blankenhaus B, Cardoso S, et al. Metabolic adaptation establishes disease tolerance to sepsis. Cell. 2017;169(1263–1275):e14.Google Scholar
- 25.Gardinassi LG, Arévalo-Herrera M, Herrera S, Cordy RJ, Tran V, Smith MR, et al. Integrative metabolomics and transcriptomics signatures of clinical tolerance to Plasmodium vivax reveal activation of innate cell immunity and T cell signaling. Redox Biol. 2018;17:158–70.PubMedPubMedCentralCrossRefGoogle Scholar
- 28.Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci USA. 2004;101:18081–6.PubMedCrossRefPubMedCentralGoogle Scholar
- 41.Petrey AC, de la Motte CA. Hyaluronan, a Crucial regulator of inflammation. Front Immunol. 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949149/. Accessed 18 June 2019